BridgeMD
New treatment option for Ureteral Stent-Related Symptom
Official title Dexamethasone for Ureteral STent Symptoms (DUSTS)
ClinicalTrials.gov ID: NCT06930690
What this study is testing
What is Dexamethasone Sodium Phosphate Injection 20 mg?
Dexamethasone Sodium Phosphate Injection 20 mg is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for ureteral stent-related symptom.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones. The main question it aims to answer is: 1) Does high-dose steroid change the quality of life score on day 2 after surgery Researchers will compare high-dose of dexamethasone (20 mg) to a standard dose of dexamethasone (4 mg) to see if a higher dose of the drug will help with urinary symptoms and pain Participants will: 1.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Age 18-70 years old
- Patients who are undergoing unilateral retrograde ureteroscopy (semi-rigid or flexible) with planned ureteral stent placement for treatment of...
- Patients who can read and understand English
- Patients who can follow up post-operatively within 7 days at Houston Methodist Hospital
You likely can't join if
- Untreated UTI
- HbA1c ≥6.5 on preoperative testing
- Patients with prior diagnosis of any type of diabetes mellitus
- Patients with immunosuppression, including chronic corticosteroid use
- Patients with bleeding disorder
- Patients with chronic liver disease, cirrhosis, and liver failure.
See the full eligibility criteria
- Age 18-70 years old
- Patients who are undergoing unilateral retrograde ureteroscopy (semi-rigid or flexible) with planned ureteral stent placement for treatment of renal/ureteral stones
- Patients who can read and understand English
- Patients who can follow up post-operatively within 7 days at Houston Methodist Hospital
- Untreated UTI
- HbA1c ≥6.5 on preoperative testing
- Patients with prior diagnosis of any type of diabetes mellitus
- Patients with immunosuppression, including chronic corticosteroid use
- Patients with bleeding disorder
- Patients with chronic liver disease, cirrhosis, and liver failure.
- Patients taking strong CYP3A4 inducers or inhibitors within two weeks of screening
- Chronic opioid analgesic use
- Congenital renal abnormalities (e.g. pelvic kidney, ureteric duplication) that may impair stent placement
- Concurrent genitourinary malignancy
- Urinary diversion
- Renal transplantation
- History of interstitial cystitis/painful bladder syndrome, prostatitis, pelvic pain due to other conditions (e.g. endometriosis)
- Neurologic disorder (e.g. spinal cord injury, multiple sclerosis, spina bifida)
- Pregnant or breastfeeding
- Patients with cognitive impairments or untreated psychiatric illness
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.